Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
2,973.0
24.0 (0.81%)

 

  • STI Straits Times Index
    2,973.0
    24.0 (0.81%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,567.1
    -10.6 (-0.67%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    29,452.6
    472.4 (1.63%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,551.4
    42.3 (1.21%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    29,663.5
    697.5 (2.41%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,338.5
    96.7 (1.55%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,925.5M
  • Value: 1,621.8M
  • Rise: 184
  • Fall: 171
  • Unch: 419

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Oceanus^0.072+0.001
CWX Global0.006-0.001
Thomson Medical0.121+0.002
Jiutian Chemical0.090+0.001
Sembcorp Marine0.153-
YZJ Shipbldg SGD1.080+0.010
Avarga0.325-0.040
Shen Yao0.003-0.001
Jasper Inv0.006-
Secura0.100-0.002

World Indices

World Indices
Name Last Change
Nasdaq 13,192.3 +72.9
HSI 29,452.6 +472.4
HSCEI 11,453.7 +206.5
Jakarta 6,338.5 +96.7
Nikkei 225 29,663.5 +697.5
SSE Comp 3,551.4 +42.3
Shanghai A 3,722.6 +44.4
Shanghai B 246.1 +2.8
KOSPI 3,099.7

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

KADMON HLDGS INC KADMON HOLDINGS
Updated on 26 Feb 2021 (End of trading day)
Last (USD): 4.590 Change: -0.010 High: 4.710 Remarks: -
Change (%): -0.22 Low: 4.440
Open 4.650 Yesterday's Close 4.6
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 2,051,326 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -0.36980 Trailing EPS (USD) e -0.55317 NAV (USD) b 0.5676
PE a - Trailing PE f - Price / NAV b 8.0867
Dividend (USD) d - Cash In Hand (USD) g 0.6177 Issued & Paid-up Shares c 171,513,000
Dividend Yield (%) d - Price / Cash In Hand g 7.431 Treasury Shares h -
Market Cap (M) 787.245 Enterprise Value (M) 695.386
Piotroski F Score 3 Exchange Code KDMN Par Value ( $ ) n.a.
52 Weeks Volatility (%) n.a. Free Float (%) 96.2
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 06 Nov 2020.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 26 Oct 2020.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference KADMON HLDGS INC NASDAQ 787.245 - - 8.0867 -
Industry Biotechnology NASDAQ 2,983.762 1438.131 - 7.3286 0.595
Local Peer AMGEN INC NASDAQ 129,906.145 17.884 17.884 13.8066 2.849
Local Peer GILEAD SCIENCES INC NASDAQ 77,154.626 627.299 627.273 4.2388 4.421
Local Peer ILLUMINA INC NASDAQ 64,109.919 97.729 97.729 13.6579 -
Local Peer MODERNA INC NASDAQ 61,259.865 - - 23.9166 -
Local Peer VERTEX PHARMACEUTICAL NASDAQ 55,254.498 20.377 20.377 6.3607 -
Local Peer REGENERON PHARMACEUTICALS INC NASDAQ 48,270.452 13.740 13.740 4.3782 -
Local Peer BIOGEN INC NASDAQ 41,569.448 10.391 10.391 3.8849 -
Local Peer ALEXION PHARMACEUTICAL INC NASDAQ 33,581.782 55.654 55.654 2.8823 -
Local Peer BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS NASDAQ 29,272.000 - - 6.8273 -
Local Peer SEAGEN INC NASDAQ 27,375.692 44.610 44.610 7.8483 -
Local Peer BIONTECH SE SPON ADS EACH REP 1 ORD SHS NASDAQ 25,968.002 - - 23.8708 -
Local Peer EXACT SCIENCES CORP NASDAQ 23,016.939 - - 8.1520 -
Other Local Peers 10X GENOMICS INC (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), INCYTE CORPORATION (NASDAQ), NOVAVAX INC (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), BIO-TECHNE CORP (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), BRIDGEBIO PHARMA INC (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), ABCELLERA BIOLOGICS INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), EXELIXIS INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), KODIAK SCIENCES INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), SANA BIOTECHNOLOGY INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), ABCAM PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), BEAM THERAPEUTICS INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), FIBROGEN INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), VERACYTE INC (NASDAQ), ARVINAS INC (NASDAQ), RELAY THERAPEUTICS INC (NASDAQ), INSMED INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), NANTKWEST INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), ALKERMES PLC (NASDAQ), SEER INC (NASDAQ), VIELA BIO INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), PRELUDE THERAPEUTICS INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), XENCOR INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), ALLOVIR INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), KYMERA THERAPEUTICS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), OCUGEN INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), IMMUNOCORE HLDGS PLC SPON ADS EACH REP ONE ORD SHS (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), C4 THERAPEUTICS INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), BIOATLA INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), PANDION THERAPEUTICS INC (NASDAQ), TRAVERE THERAPEUTICS INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), TRANSLATE BIO INC (NASDAQ), SHATTUCK LABS INC (NASDAQ), PRECIGEN INC (NASDAQ), ZENTALIS PHARMACEUTICALS INC (NASDAQ), REGENXBIO INC (NASDAQ), APPLIED MOLECULAR TRANSPORT INC (NASDAQ), VOR BIOPHARMA INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), IMMUNOGEN INC (NASDAQ), UNIQURE N.V. (NASDAQ), COMPASS PATHWAYS PLC UNSPON ADS REP 1 ORD SHS (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), NKARTA INC (NASDAQ), PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS (NASDAQ), IMMUNOVANT INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), GRACELL BIOTECHNOLOGIES INC SPON ADS EACH REP 5 ORD SHS (NASDAQ), ITEOS THERAPEUTICS INC (NASDAQ), ALECTOR INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), MACROGENICS INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), PERSONALIS INC (NASDAQ), CYTOKINETICS INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), OMEROS CORP (NASDAQ), VAXCYTE INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), PLIANT THERAPEUTICS INC (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), MORPHIC HOLDING INC (NASDAQ), 4D MOLECULAR THERAPEUTICS INC (NASDAQ), MIMEDX GROUP INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), VANDA PHARMACE INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), BLACK DIAMOND THERAPEUTICS INC (NASDAQ), CORTEXYME INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), EPIZYME INC (NASDAQ), TAYSHA GENE THERAPIES INC (NASDAQ), HUMANIGEN INC (NASDAQ), INHIBRX INC (NASDAQ), PASSAGE BIO INC (NASDAQ), DYNE THERAPEUTICS INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), AVIDITY BIOSCIENCES INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), PROTHENA CORP PLC (NASDAQ), RADIUS HEALTH INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC SPON ADS EACH REP 6 ORD SHS (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), VAXART INC (NASDAQ), CHIMERIX INC (NASDAQ), MERUS B V (NASDAQ), CURIS INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), ATHIRA PHARMA INC (NASDAQ), SIGILON THERAPEUTICS INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), COMPUGEN (NASDAQ), ASPIRA WOMENS HEALTH INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), AGENUS INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), AKOUOS INC (NASDAQ), POSEIDA THERAPETUICS INC (NASDAQ), IMMATICS N V (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), AFFIMED N V (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), ATRECA INC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), ALTIMMUNE INC (NASDAQ), FOGHORN THERAPEUTICS INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), ARDELYX INC (NASDAQ), INVENTIVA SA SPON ADS EACH REP 1 ORD SHS (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), SUMMIT THERAPEUTICS INC (NASDAQ), XBIOTECH INC (NASDAQ), GERON CORP (NASDAQ), IVERIC BIO INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), TERNS PHARMACEUTICALS INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), LANDOS BIOPHARMA INC (NASDAQ), FREELINE THERAPEUTICS HLDGS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), COGENT BIOSCIENCES INC (NASDAQ), NEOLEUKIN THERAPEUTICS INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), SPRUCE BIOSCIENCES INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), SENSEI BIOTHERAPEUTICS INC (NASDAQ), ADICET BIO INC (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), DECIBEL THERAPEUTICS INC (NASDAQ), AVROBIO INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), BIOVIE INC (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), SESEN BIO INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), UROGEN PHARMA LTD (NASDAQ), IMMUNOME INC (NASDAQ), PORTAGE BIOTECH INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), ONCORUS INC (NASDAQ), ATHERSYS INC (NASDAQ), XOMA CORP (NASDAQ), VERASTEM INC (NASDAQ), OPTHEA LIMITED SPON ADS EACH REPR 8 ORD SHS (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), GREENWICH LIFESCIENCES INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), FORTE BIOSCIENCES INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), AEGLEA BIOTHERAPEUTICS INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), 9 METERS BIOPHARMA INC (NASDAQ), TREVENA INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), NEXTCURE INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), BELLUS HEALTH INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), CHECKMATE PHARMACEUTICALS INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), KAMADA LTD (NASDAQ), MEDICINOVA INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), LARIMAR THERAPEUTICS INC (NASDAQ), CABALETTA BIO INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), IMMUNOPRECISE ANTIBODIES LTD (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), CHIASMA INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), IMV INC (NASDAQ), METACRINE INC (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), INMUNE BIO INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), EVOGENE LTD (NASDAQ), AXCELLA HEALTH INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), MEDICENNA THERAPEUTICS CORP (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), EQUILLIUM INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), ENOCHIAN BIOSCIENCES INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), AZIYO BIOLOGICS INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), ORGENESIS INC (NASDAQ), GLYCOMIMETICS INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), SIO GENE THERAPIES INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), LONGEVERON INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), CONTRAFECT CORP (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), OTONOMY INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), EVAXION BIOTECH AS SPON ADS EACH REP 1 ORD SHS (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), SYNLOGIC INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), ARAVIVE INC (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), AIKIDO PHARMA INC (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), LUMOS PHARMA INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), CELYAD ONCOLOGY SPON ADS EACH REPR 1 ORD SHS (NASDAQ), INFLARX N V (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), NEUROBO PHARMACEUTICALS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), ADVAXIS INC (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), COHBAR INC (NASDAQ), SAVARA INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), WINDTREE THERAPEUTICS INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), MONOPAR THERAPEUTICS INC (NASDAQ), VACCINEX INC (NASDAQ), VIRACTA THERAPEUTICS INC (NASDAQ), RECRO PHARMA INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), LIXTE BIOTECHNOLOGY HOLDINGS INC (NASDAQ), APPLIED DNA SCIENCES INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), VIRIDIAN THERAPEUTICS INC (NASDAQ), BIOCARDIA INC (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), ANPAC BIO MEDICAL SCIENCE CO LTD SPON ADS EACH REPR 1 ORD SHS CLASS A (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), KIROMIC BIOPHARMA INC (NASDAQ), SOLIGENIX INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), ATYR PHARMA INC (NASDAQ), ADITX THERAPEUTICS INC (NASDAQ), PRECIPIO INC (NASDAQ), SONNET BIOTHERAPEUTICS HLDGS INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), CYCLO THERAPEUTICS INC (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), CYCLACEL PHARMACEUTICALS INC (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), HISTOGEN INC (NASDAQ), GEOVAX LABS INC (NASDAQ), INMED PHARMACEUTICALS INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 5 ORD SHS(R/S) (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), SENECA BIOPHARMA INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), BRIACELL THERAPEUTICS CORP (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), SENESTECH INC (NASDAQ), BENITEC BIOPHARMA INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ)
Global Peer CSL LTD ASX 122,980.643 39.212 32.314 11.6378 1.086
Global Peer WUXI BIO HKEx 430,698.345 374.657 299.115 28.8323 -
Global Peer BEIGENE HKEx 234,504.324 - - - -
Global Peer SINO BIOPHARM HKEx 163,115.932 53.145 63.741 4.5258 0.615
Global Peer ZAI LAB-SB HKEx 100,787.709 - - 27.9378 -
Global Peer EMERGENT BIOSOLUTIONS INC NYSE 5,116.800 16.771 16.771 3.5361 -
Global Peer JOINN HKEx 37,773.782 177.348 154.785 34.2004 -
Global Peer Lonza SGX 5,940.891 4.560 4.560 0.5844 5.624
Global Peer GENSCRIPT BIO HKEx 29,084.523 - - 3.9779 -
Global Peer 3SBIO HKEx 20,425.108 18.499 13.603 1.7461 -
Other Global Peers ARCUS BIOSCIENCES INC (NYSE), NUVATION BIO INC (NYSE), MYOVANT SCIENCES LTD (NYSE), JACOBIO-B (HKEx), JW THERAP-B (HKEx), VIVA BIOTECH (HKEx), ALPHAMAB-B (HKEx), FRONTAGE (HKEx), HAOHAI BIOTEC (HKEx), POLYNOVO LIMITED (ASX), JHBP-B (HKEx), ASCENTAGE-B (HKEx), MESOBLAST LTD (ASX), TELIX PHARMACEUTIC (ASX), KINTOR PHARMA-B (HKEx), ACTINIUM PHARMACEUTICALS INC (NYSE American), SINOMAB BIO-B (HKEx), DPHARMA (Bursa), LEE'S PHARM (HKEx), ASCLETIS-B (HKEx), SQZ BIOTECHNOLOGIES CO (NYSE), OPTHEA LIMITED (ASX), IMUGENE LIMITED (ASX), LINEAGE CELL THERAPEUTICS INC (NYSE American), 22ND CENTURY GROUP INC (NYSE American), ANTEOTECH LIMITED (ASX), ESSEX BIO-TECH (HKEx), NANOVIRICIDES INC (NYSE American), BIONOMICS LTD (ASX), NEXT SCIENCE LTD (ASX), IMMUTEP LTD (ASX), CEL-SCI CORP (NYSE American), IBIO INC (NYSE American), ENZO BIOCHEM INC (NYSE), KAZIA THERAPEUTICS LIMITED (ASX), NEUREN PHARMACEUTICALS LTD (ASX), PALATIN TECHNOLOGIES INC (NYSE American), ARMATA PHARMACEUTICALS INC (NYSE American), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), AIM IMMUNOTECH INC (NYSE American), UNI-BIO GROUP (HKEx), LEAF RESOURCES LTD (ASX), SYNTHETIC BIOLOGICS INC (NYSE American), CHIMERIC THERAPEUTICS LTD (ASX), REGENT PACIFIC (HKEx), CYNATA THERAPEUTICS LTD (ASX), GENETIC TECHNOLOGIES (ASX), ALTERITY THERAPEUTICS LIMITED (ASX), MEMPHASYS LTD (ASX), INDIA GLOBALIZATION CAPITAL INC (NYSE American), PRESCIENT THERAPEUTICS LIMITED (ASX), ORAGENICS INC (NYSE American), INVEX THERAPEUTICS LTD NPV (ASX), CT ENTERPRISE (HKEx), BIOTRON (ASX), PATRYS LIMITED (ASX), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), Suntar Eco-City (SGX), BIOSINO BIO-TEC (HKEx), ADALTA LTD (ASX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), AUSTRALIAN PRIMARY HEMP LTD (ASX), CONSTELLATION TECHNOLOGIES LTD (ASX), ACTINOGEN MEDICAL LTD (ASX), REGENEUS LTD (ASX), RHINOMED LIMITED (ASX), AMPLIA THERAPEUTICS LTD (ASX), NOVABAY PHARMACEUTICALS INC (NYSE American), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), HOLISTA COLLTECH LIMITED (ASX), ANATARA LIFESCIENCES LTD (ASX), NANOLLOSE LTD (ASX), LIVING CELL TECHNOLOGIES (ASX), HAO WEN HLDGS (HKEx), CRYOSITE (ASX), FACTOR THERAPEUTICS LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.200
-4.18 %
10 Days --0.050
-1.08 %
20 Days --0.430
-8.57 %
Medium Term Return 3 Months -+0.230
+5.28 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 3.145 - 5.730 Change From 1 Year Low +1.445 % Change From 1 Year Low (%) +45.95
Change From 1 Year High -1.140 % Change From 1 Year High (%) -19.90
2 Years Range 3.145 - 5.730 Change From 2 Years Low +1.445 % Change From 2 Years Low (%) +45.95
Change From 2 Years High -1.140 % Change From 2 Years High (%) -19.90
5 Years Range 3.145 - 5.730 Change From 5 Years Low +1.445 % Change From 5 Years Low (%) +45.95
Change From 5 Years High -1.140 % Change From 5 Years High (%) -19.90
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY.

Historical Price Data

Date Open High Low Close Volume VWAP
26 Feb 2021 4.650 4.710 4.440 4.590 2,051,326 -
25 Feb 2021 4.810 4.910 4.580 4.600 1,939,599 -
24 Feb 2021 4.700 4.880 4.630 4.855 1,484,687 -
23 Feb 2021 4.680 4.870 4.540 4.625 3,698,439 -
22 Feb 2021 5.000 5.040 4.790 4.790 5,413,138 -
19 Feb 2021 4.920 5.160 4.870 5.050 5,518,380 -
18 Feb 2021 4.860 5.030 4.700 4.890 4,837,193 -
17 Feb 2021 4.750 4.910 4.620 4.890 6,921,132 -
16 Feb 2021 4.800 4.800 4.570 4.670 4,880,077 -
12 Feb 2021 4.850 4.900 4.600 4.640 5,213,576 -
11 Feb 2021 4.830 4.990 4.760 4.850 11,799,300 -
10 Feb 2021 5.550 5.620 5.220 5.350 2,513,669 -
09 Feb 2021 5.520 5.590 5.360 5.470 1,414,462 -
08 Feb 2021 5.320 5.570 5.190 5.510 3,679,479 -
05 Feb 2021 5.215 5.730 4.930 5.320 6,237,675 -
04 Feb 2021 4.990 5.065 4.880 4.910 1,774,524 -
03 Feb 2021 5.120 5.170 4.960 4.980 2,271,696 -
02 Feb 2021 5.100 5.115 4.860 5.090 2,025,459 -
01 Feb 2021 4.850 5.050 4.770 5.020 2,601,029 -
29 Jan 2021 4.880 5.255 4.770 4.800 4,817,622 -
28 Jan 2021 4.790 5.010 4.580 4.780 4,073,238 -
27 Jan 2021 5.190 5.360 4.830 4.830 4,343,529 -
Summary
Current 2 Weeks
(12 Feb 2021 to 26 Feb 2021)
4.850 5.160 4.440 4.590 41,957,547 -
Previous 2 Weeks
(29 Jan 2021 to 11 Feb 2021)
4.880 5.255 4.440 4.850 39,134,915 -
4 Weeks from
(30 Dec 2020 to 28 Jan 2021)
4.070 5.160 4.060 4.780 73,111,449 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.